| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | Respiratoire
> Maladies pulmonaires | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Over 100,000 | National | Regularly | 119011106646 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | Neuromusculaire
> Dystrophie musculaire | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | 1 000 | National | Regularly | 119021570524 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | Cancer
> Cancer : la plupart des types | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | Rein
> Maladies rénales | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Do not know | National | Regularly | 119051003447 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines. | Respiratoire
> Asthme | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Over 100,000 | National | Regularly | 119051065145 |
| PBAC [Pharmaceutical Benefits Advisory Committee] comments. | Peau
> Dermatite atopique/eczéma | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Over 100,000 | National | Regularly | 119051082840 |
| HTA [Health Technology Assessment] — lived experience. | Respiratoire
> Maladies pulmonaires | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Over 100,000 | National | Regularly | 119051865995 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Rare
> Maladies rares : génétiques | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | 1 000 | National | Sometimes | 119054286714 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | Gastro-intestinal
> IBD | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Over 100,000 | National | Regularly | 119058351283 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | Cardiovasculaire
> Maladies cardiovasculaires et cardiaques | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | Do not know | International | Regularly | 119061299937 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | Santé mentale
> Santé mentale : la plupart des affections | Partenariat réglementaire
> Participer aux évaluations des technologies de santé (ETS) et aux examens de remboursement | 10 000 | National | Sometimes | 119074282308 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | Respiratoire
> Asthme | Partenariat réglementaire
> Contribuer aux soumissions d'autorisation de mise sur le marché | Over 100,000 | National | Regularly | 119051065145 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | Neuromusculaire
> Dystrophie musculaire | Partenariat réglementaire
> Assister/faciliter des réunions avec des décideurs politiques/régulateurs | 1 000 | National | Regularly | 119021570524 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. | Santé mentale
> Santé mentale : la plupart des affections | Partenariat réglementaire
> Avec d'autres défenseurs des soins de santé | 10 000 | National | Sometimes | 119074282308 |
| Regular advocacy and lobbying to all levels of government on new and current diabetes medications and technology. | Endocrinien
> Diabète (types 1 et 2) | Influencer les politiques et la législation
> Influencer les politiques et la législation en matière de santé | Over 100,000 | National | Regularly | 119023443093 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | Respiratoire
> Asthme | Influencer les politiques et la législation
> Influencer les politiques et la législation en matière de santé | Over 100,000 | National | Regularly | 119051065145 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | Gastro-intestinal
> IBD | Influencer les politiques et la législation
> Influencer les politiques et la législation en matière de santé | Over 100,000 | National | Regularly | 119058351283 |
| Where possible, we add our advocacy voice to decision-makers. | Neuromusculaire
> Dystrophie musculaire | Influencer les politiques et la législation
> Influencer les politiques et la législation en matière de santé | 1 000 | National | Rarely | 119070072574 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | Rein
> Maladies rénales | Influencer les politiques et la législation
> Participer aux audiences publiques et aux consultations | Do not know | National | Regularly | 119051003447 |
| Public submissions. | Recherche médicale
> Recherche médicale | Influencer les politiques et la législation
> Participer aux audiences publiques et aux consultations | 100 | National | Sometimes | 119075599019 |
| Pre-Budget Submissions, Advocacy activities, Meetings. | Rhumatismal
> Maladies rhumatismales : la plupart des types | Influencer les politiques et la législation
> Mobiliser les parlementaires et les dirigeants politiques | Over 100,000 | National | Regularly | 119017682842 |
| Weight loss drugs, general medicine costs. | Défense des droits des patients
> Droits du patient | Plaidoyer pour la tarification et l'accessibilité financière
> Plaider pour une tarification équitable des médicaments | 100 000 | National | Sometimes | 119055318270 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | Gastro-intestinal
> IBD | Plaidoyer pour la tarification et l'accessibilité financière
> Plaider pour une tarification équitable des médicaments | Over 100,000 | National | Regularly | 119058351283 |
| Pricing. | Rhumatismal
> Lupus | Plaidoyer pour la tarification et l'accessibilité financière
> Plaider pour une tarification équitable des médicaments | 5 000 | International | Regularly | 119058972997 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | Neurologique
> Neurologique : autre | Plaidoyer pour la tarification et l'accessibilité financière
> Plaider pour une tarification équitable des médicaments | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | Infectieux
> Immunisation | Plaidoyer pour la tarification et l'accessibilité financière
> Plaidoyer pour l'inclusion du produit dans les listes de remboursement/formulaires nationaux | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | Os
> Fibrodysplasie ossifiante progressive (FOP) | Plaidoyer pour la tarification et l'accessibilité financière
> Plaidoyer pour l'inclusion du produit dans les listes de remboursement/formulaires nationaux | 100 | National | Rarely | 119044789085 |
| Australia's PBS [Pharmaceutical Benefits Scheme] listings as an example. | Rein
> Maladies rénales | Plaidoyer pour la tarification et l'accessibilité financière
> Plaidoyer pour l'inclusion du produit dans les listes de remboursement/formulaires nationaux | 5 000 | National | Regularly | 119050789619 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Rare
> Maladies rares : génétiques | Plaidoyer pour la tarification et l'accessibilité financière
> Plaidoyer pour l'inclusion du produit dans les listes de remboursement/formulaires nationaux | 1 000 | National | Sometimes | 119054286714 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | Santé mentale
> Santé mentale : la plupart des affections | Plaidoyer pour la tarification et l'accessibilité financière
> Plaidoyer pour l'inclusion du produit dans les listes de remboursement/formulaires nationaux | 10 000 | National | Sometimes | 119074282308 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | Neuromusculaire
> Dystrophie musculaire | Amélioration des voies d'accès
> Faciliter l'accès équitable aux médicaments/soins de santé | 1 000 | National | Regularly | 119021570524 |
| Weight loss drugs, general medicine costs. | Défense des droits des patients
> Droits du patient | Amélioration des voies d'accès
> Faciliter l'accès équitable aux médicaments/soins de santé | 100 000 | National | Sometimes | 119055318270 |
| Regulations and restrictions regarding prescribing of antivirals for COVID to our patient cohort [neurological conditions]. | Neurologique
> Neurologique : autre | Amélioration des voies d'accès
> Faciliter l'accès équitable aux médicaments/soins de santé | 5 000 | National | Rarely | 119056702514 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | Cardiovasculaire
> Maladies cardiovasculaires et cardiaques | Amélioration des voies d'accès
> Faciliter l'accès équitable aux médicaments/soins de santé | Do not know | International | Regularly | 119061299937 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | Neurologique
> Neurologique : autre | Amélioration des voies d'accès
> Faciliter l'accès équitable aux médicaments/soins de santé | We do not communicate with patients directly | National | Regularly | 119069368666 |
| Through an HTA [Health Technology Assessment] implementation review. | Neurologique
> Neurologique : autre | Amélioration des voies d'accès
> Faciliter l'accès équitable aux médicaments/soins de santé | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | Infectieux
> Immunisation | Amélioration des voies d'accès
> Plaider pour un accès plus large aux vaccins | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | Os
> Fibrodysplasie ossifiante progressive (FOP) | Amélioration des voies d'accès
> Améliorer l'accès aux thérapies rares/ultra-rares | 100 | National | Rarely | 119044789085 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | Rein
> Maladies rénales | Contribution des patients fondée sur des données probantes
> Utilisez les informations sur les patients pour éclairer les décisions | Do not know | National | Regularly | 119051003447 |
| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | Respiratoire
> Maladies pulmonaires | Contribution des patients fondée sur des données probantes
> Exploiter les témoignages de patients et les récits d'expériences vécues | Over 100,000 | National | Regularly | 119011106646 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | Cancer
> Cancer : la plupart des types | Contribution des patients fondée sur des données probantes
> Exploiter les témoignages de patients et les récits d'expériences vécues | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| HTA [Health Technology Assessment] — lived experience. | Respiratoire
> Maladies pulmonaires | Contribution des patients fondée sur des données probantes
> Exploiter les témoignages de patients et les récits d'expériences vécues | Over 100,000 | National | Regularly | 119051865995 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | Santé mentale
> Santé mentale : la plupart des affections | Contribution des patients fondée sur des données probantes
> Exploiter les témoignages de patients et les récits d'expériences vécues | 10 000 | National | Sometimes | 119074282308 |
| Pricing, clinical trials. | Rhumatismal
> Lupus | Diagnostic et livraison de médicaments
> Collaborer sur la conception d'essais cliniques | 5 000 | International | Regularly | 119058972997 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Rare
> Maladies rares : génétiques | Diagnostic et livraison de médicaments
> Soutenir le dépistage et la détection précoce | 1 000 | National | Sometimes | 119054286714 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Rare
> Maladies rares : génétiques | Gouvernance institutionnelle
> Assurer la représentation au sein des organes consultatifs gouvernementaux | 1 000 | National | Sometimes | 119054286714 |
| Preterm Infants Parents Association [PIPA] has representatives on numerous hospital and Queensland Health Department committees. | Santé des enfants
> Néonatal | Gouvernance institutionnelle
> Assurer la représentation au sein des organes consultatifs gouvernementaux | 5 000 | Regional | Regularly | 119074312093 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | Neurologique
> Neurologique : autre | Gouvernance institutionnelle
> Travailler efficacement au sein de réseaux multi-parties prenantes | We do not communicate with patients directly | National | Regularly | 119069368666 |
interactions
actions et plaidoyer
14 mentions
